- Single-center, randomized, double-blind, placebo-controlled pilot trial of 100 critically ill adults with CAM-ICU-confirmed delirium in surgical and trauma ICUs.
- Patients received 2 mg guanfacine or matching placebo nightly for up to 14 days, or until ICU discharge or delirium resolution.
- Median delirium and coma-free days were 2 (IQR 0-6) with guanfacine versus 1 (IQR 0-4) with placebo (p = 0.02) in unadjusted analyses, but not significant after adjustment.
- Feasibility targets were mostly met, with 100% adherence, retention, and data completeness, though COVID-19 limited recruitment to 0.9 patients/week; authors judge the signal worth a multicenter trial.
Neuro
Research from anesthesiology, pain and critical care journals, sourced from PubMed.
Sorted by publication date, not import date. Recent filters exclude papers with only a publication year; find those under All years.
AI-generated abstract summaries can contain errors. Verify findings against the original paper before applying them to patient care.
Last successful paper check: 16 Nov 2026 17:18 UTC.
0 newly discovered papers saved; these are not necessarily published today.
2 papers awaiting AI summaries. Summary processing had an error; paper-fetch status is separate.
Background checks run while the server is active. This does not guarantee a daily run if hosting sleeps.
2 papers awaiting AI summaries. Summary processing had an error; paper-fetch status is separate.
Background checks run while the server is active. This does not guarantee a daily run if hosting sleeps.
- Single-centre, double-blind randomised noninferiority trial of 686 adults having elective neurovascular surgery, analysed as a modified intention-to-treat population.
- Patients received remimazolam-based TIVA with flumazenil reversal at emergence or propofol-based TIVA, both with remifentanil.
- Postoperative delirium within 5 days occurred in 12.8% (44/344) with remimazolam and 10.8% (37/342) with propofol; risk difference 1.97 percentage points (95% CI -2.85 to 6.80).
- Remimazolam met the prespecified noninferiority criterion, and that group had less intraoperative hypotension below a MAP of 65 mm Hg and more operating-room extubation.
- Pragmatic randomized trial at Mount Sinai Hospital including 7294 surgical patients with preoperative cognitive impairment identified by NLP, MMSE scores, or diagnostic codes.
- Patients were randomized to an AI-driven, non-interruptive EHR decision support tool aimed at anesthesia team adherence, or to routine perioperative care.
- Only 1255 patients (17.2%) had documented delirium assessments; delirium occurred in 35.1% of intervention and 32.7% of control patients (P = .37).
- Best practice adherence did not differ significantly between groups (all P > .05), and the authors call for further work on using these tools effectively.
- Randomized trial of 178 analyzed patients undergoing posterior lumbar interbody fusion, comparing deep and moderate neuromuscular blockade.
- Deep neuromuscular blockade was compared with moderate blockade, with 3-month chronic postsurgical pain incidence as the primary outcome.
- Chronic pain at 3 months was 19.1% with deep block vs 34.8% with moderate block (RR 0.6; 95% CI 0.3-0.9; P = .018), with no significant difference at 6 months (RR 0.8; 95% CI 0.4-1.5; P = .423).
- Deep block was linked to lower CK, myoglobin and LDH on day 1 and better paraspinal muscle preservation on 6-month MRI; authors attribute benefit to less muscle injury.
- This delirium-focused secondary analysis of a single-centre, double-blind, placebo-controlled trial enrolled adults having head and neck cancer surgery with free-flap reconstruction.
- Patients received intraoperative dexmedetomidine at 0.3 μg/kg/h until 1 hour before surgery ended, or comparable volumes of saline placebo.
- Delirium over the first 5 postoperative days occurred in 14.9% (7/47) of dexmedetomidine patients versus 34.7% (17/49) of placebo patients (adjusted OR 0.31, 95% CI 0.10-0.92; p = 0.036).
- Pain and early sleep were reported as improved with dexmedetomidine, and haemodynamic adverse events and postoperative complications did not differ significantly between groups.
- Pragmatic, open-label, multicenter randomized trial of 2508 adults aged 50 or older having elective major noncardiac surgery at 49 UK NHS hospitals.
- Patients were randomized 1:1 to maintenance of general anesthesia with propofol TIVA or volatile inhalational agents, with other perioperative care left to clinician discretion.
- Days alive and at home at 30 days were similar (22.5 vs 22.4 days; incidence rate ratio 1.00, 95% CI 0.99-1.02; adjusted P = .68).
- TIVA was associated with lower reported thirst, hoarseness, and nausea/vomiting; major complications (12.4% overall) did not differ between groups.
- Single-center randomized non-inferiority trial in China with 316 randomized elderly patients (of 535 screened) undergoing elective unilateral total knee or hip arthroplasty.
- Intranasal dexmedetomidine the night before surgery plus IV saline at induction was compared with intranasal saline plus IV dexmedetomidine before induction.
- Delirium within 3 days by CAM occurred in 9.5% vs 7.6%; rate difference 0.02 (95% CI -0.04 to 0.08), reported P<0.001, meeting non-inferiority.
- Authors also reported better sleep the night before surgery, lower preoperative anxiety and pain scores, and fewer adverse events with the intranasal route.